C12N 2770/28011
Hepeviridae
C12N2770/28011 (Hepeviridae) appears on 82 US grants and 81 published applications in this corpus.
Search patents in C12N- Granted patents
- 82
- Published applications
- 81
- Assignees
- 64
- Inventors
- 153
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 7 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 1 |
| 2002 | 6 | 1 |
| 2003 | 2 | 10 |
| 2004 | 3 | 3 |
| 2005 | 1 | 2 |
| 2006 | 4 | 3 |
| 2007 | 1 | 1 |
| 2008 | 1 | 0 |
| 2009 | 2 | 0 |
| 2010 | 2 | 6 |
| 2011 | 1 | 1 |
| 2012 | 1 | 4 |
| 2013 | 1 | 2 |
| 2014 | 5 | 4 |
| 2015 | 1 | 4 |
| 2016 | 2 | 6 |
| 2017 | 6 | 5 |
| 2018 | 2 | 2 |
| 2019 | 6 | 5 |
| 2020 | 2 | 3 |
| 2021 | 2 | 4 |
| 2022 | 1 | 1 |
| 2023 | 2 | 3 |
| 2024 | 1 | 4 |
| 2025 | 3 | 2 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/28111HepevirusIndexing code66
- C12N 2770/28022New viral proteins or individual genes, new structural or functional aspects ofIndexing code10
- C12N 2770/28021Viruses as suchIndexing code5
- C12N 2770/28033Use of viral protein as therapeutic agent other than vaccineIndexing code5
- C12N 2770/28034Use of virus or viral component as vaccineIndexing code5
- C12N 2770/28041Use of virus, viral particle or viral elements as a vectorIndexing code1
- C12N 2770/28023Virus like particles [vlp]Indexing code0
- C12N 2770/28031Uses of virus other than therapeutic or vaccineIndexing code0
All 13 subgroupsShow fewer
- C12N 2770/28032Use of virus as therapeutic agent, other than vaccineIndexing code0
- C12N 2770/28051Methods of production or purification of viral materialIndexing code0
- C12N 2770/28061Methods of inactivation or attenuationIndexing code0
- C12N 2770/28071Demonstrated in vivo effectIndexing code0
- C12N 2770/28088For redistributionIndexing code0
Recent patents
- Hepatitis E virus-like particles (VLPs) derived from consensus sequences19 May 2026US 12,630,844 B2Novo Capsid Technologies LLC
- Norovirus S particle based vaccines and methods of making and using same3 Feb 2026US 12,539,327 B2Children's Hospital Medical Center
- Compositions and methods for antigen targeting to CD18029 Jul 2025US 12,371,672 B2University of Washington
- Virus-like nanoparticles for oral delivery25 Feb 2025US 12,234,260 B2The Regents of the University of California
- Hepatitis c virus E1/E2 heterodimers and methods of producing same21 Jan 2025US 12,202,859 B2The Governors of the University of Alberta
- Hepatitis e virus-like particles (vlps) derived from consensus sequences10 Sep 2026US 2026/0263379 A1Novo Capsid Technologies LLC
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Methods and compositions of quaternary immunomodulatory nanoparticles for medical applications and immunotherapy25 Jun 2026US 2026/0174841 A1
- Virus-like nanocapsid for oral delivery of insulin11 Jun 2026US 2026/0159817 A1The Regents of the University of California
- Hepatitis e virus-like particles (vlps) derived from consensus sequences24 Jul 2025US 2025/0236885 A1Novo Capsid Technologies LLC
Most cited
By later US patents
- Synthesis deprotection analysis and purification of RNA and ribozymes56US 5,831,071 ARibozyme Pharmaceuticals, Inc. · 1998
- Synthesis, deprotection, analysis and purification of RNA and ribozymes56US 6,469,158 B1Ribozyme Pharmaceuticals, Inc. · 2002
- Synthesis, deprotection, analysis and purification of RNA and ribozymes50US 6,353,098 B1Ribozyme Pharmaceuticals, Inc. · 2002
- N-phthaloyl-protected 2'-amino-nucleoside phosphoramdites46US 5,631,360 ARibozyme Pharmaceuticals, Inc. · 1997
- Antisense antiviral compound and method for treating ssRNA viral infection37US 8,906,872 B2Sarepta Therapeutics, Inc. · 2014